All nine patients treated with a personalized cancer vaccine following removal of their tumors remained cancer-free at a median data cut-off of 34.7 months.

Share and Cite: Hinz, B. and Kenyon, J. (2025) Getting to a Diagnosis: A Rare Case of TFE3 Translocation Renal Cell Carcinoma ...

A highly vascularized cancer that is especially reliant on tumor endothelial cells is clear cell renal cell carcinoma (ccRCC). Almost 80% of malignant tumors in the kidney are ccRCC ... She found that ...

Researchers evaluated a neoantigen-targeting personalized cancer vaccine in patients with high-risk, fully resected clear ...

American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 13 ...

Multiple therapeutic options are available for the management of patients with upper urinary tract transitional cell carcinoma ... patients with a normal contralateral kidney who have small ...

American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA was host to the ...

In a phase 1 trial, all 9 patients with renal cell carcinoma treated with a neoantigen-targeting personalized cancer vaccine ...

Clear cell renal cell carcinoma (ccRCC ... antiprogrammed cell PD-1 IgG4k antibody that has been approved in China for the treatment of kidney carcinoma. The utilization of ICIs has shown significant ...

Renal regulation of glucose metabolism mainly includes gluconeogenesis, glomerular glucose filtration, and proximal convoluted tubules glucose reabsorption. In the fasting state of normal individuals, ...